Prognosis for fragile cancer patients remains very poor. Bio-Path aims to meet the need that exists for non-toxic therapies for fragile cancer patients who are ineligible for high-dose chemotherapy.
The company’s lead candidate is prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, for the treatment of acute myeloid leukemia (AML). Prexigebersen is being assessed in a Phase 2 trial in combination with front-line therapy. The Company’s second product BP1002 (Liposomal Bcl-2 Antisense) is being evaluated in Phase 1 trials in lymphoma and AML.
Our pipeline consists of antisense RNAi nanoparticle drugs in clinical development for some of the most lethal blood cancers and solid tumors.